Long-read sequencing reveals the RNA isoform repertoire of neuropsychiatric risk genes in human brain

- 3
- 4 Ricardo De Paoli-Iseppi^{1*}, Shweta Joshi¹, Josie Gleeson¹, Yair David Joseph Prawer¹, Yupei You^{2,3}, Ria
- 5 Agarwal¹, Anran Li¹, Anthea Hull¹, Eloise Marie Whitehead¹, Yoonji Seo¹, Rhea Kujawa¹, Raphael Chang¹,
- 6 Mriga Dutt¹, Catriona McLean^{4,5}, Benjamin Leo Parker¹, Michael Ben Clark^{1*}
- 7 ¹Department of Anatomy and Physiology, The University of Melbourne, Parkville, VIC, Australia
- ²School of Mathematics and Statistics/Melbourne Integrative Genomics, The University of Melbourne,
 Parkville, VIC, Australia
- 10 ³The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
- 11 ⁴Department of Anatomical Pathology, Alfred Health, Melbourne, Victoria, Australia
- 12 ⁵Victorian Brain Bank, The Florey, Parkville, Victoria, Australia
- 13 *Corresponding authors

14 Abstract

- 15 Neuropsychiatric disorders are highly complex conditions and the risk of developing a disorder has
- 16 been tied to hundreds of genomic variants that alter the expression and/or products (isoforms) made
- by risk genes. However, how these genes contribute to disease risk and onset through altered
- 18 expression and RNA splicing is not well understood. Combining our new bioinformatic pipeline
- 19 IsoLamp with nanopore long-read amplicon sequencing, we deeply profiled the RNA isoform
- 20 repertoire of 31 high-confidence neuropsychiatric disorder risk genes in human brain. We show most
- risk genes are more complex than previously reported, identifying 363 novel isoforms and 28 novel
- exons, including isoforms which alter protein domains, and genes such as *ATG13* and *GATAD2A*
- 23 where most expression was from previously undiscovered isoforms. The greatest isoform diversity
- 24 was present in the schizophrenia risk gene *ITIH4*. Mass spectrometry of brain protein isolates
- 25 confirmed translation of a novel exon skipping event in ITIH4, suggesting a new regulatory
- 26 mechanism for this gene in brain. Our results emphasize the widespread presence of previously
- 27 undetected RNA and protein isoforms in brain and provide an effective approach to address this
- 28 knowledge gap. Uncovering the isoform repertoire of neuropsychiatric risk genes will underpin future
- analyses of the functional impact these isoforms have on neuropsychiatric disorders, enabling the
- 30 translation of genomic findings into a pathophysiological understanding of disease.


31 Keywords

32 RNA, splicing, neuropsychiatric, brain, long-read, nanopore, isoform

33 Introduction

- 34 Over 90% of multi-exonic human genes undergo alternative splicing (AS), a process that enables
- 35 genes to produce multiple mRNA products (RNA isoforms) [1]. Common AS events include exon
- 36 skipping, intron retention and alternative 5' and 3' exonic splice sites [2]. These mRNA alterations
- 37 can impact the open reading frame (ORF) and/or alter post-transcription regulation of an RNA. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.


- 38 increasing both transcriptomic and proteomic diversity [1, 3, 4]. AS has been established as an
- important regulator of organ development and physiological functions and is highly regulated under 39
- 40 normal conditions [5, 6]. Conversely, aberrant RNA splicing has been linked to the development of
- cancer, autoimmune and neurodevelopmental disorders [7-11]. AS plays an especially important role 41
- in the brain, which has a distinct splicing program including the largest number of tissue specific 42
- exons and frequent use of microexons [12]. Numerous studies have reported crucial roles for AS in 43
- brain development and dysregulation in disease [13, 14]. 44
- 45 Neuropsychiatric or mental health disorders (MHDs) including schizophrenia (SZ), major depressive
- disorder (MDD), autism spectrum disorder (ASD) and bipolar disorder (BD) can carry significant 46
- morbidity for affected individuals [15]. Comorbidities, delayed diagnoses and stigma surrounding 47
- 48 MHDs also present a significant challenge to individuals and their families [16]. However, treatment
- 49 options remain limited or are not well tolerated or effective in some individuals and the underlying
- 50 aetiology of disease and risk remains poorly understood [17-19]. Recently, genome wide association
- 51 studies (GWAS) have revealed hundreds of common single nucleotide polymorphisms (SNPs) that are associated with risk of developing neuropsychiatric disease [20-25]. Confirmatory studies
- 52
- 53 including transcriptome wide association studies (TWAS), summary data-based Mendelian
- randomization (SMR) [26], multimarker analysis of genomic annotation (MAGMA) and variants (H-54
- 55 MAGMA [27], nMAGMA [28]) and functional genomics have helped to identify the risk genes at
- these loci and also showed a considerable number of risk loci are shared between disorders [29]. 56
- 57 Understanding how risk variants affect risk genes is not straightforward, the vast majority of risk 58 variants are found in non-coding parts of the genome and are expected to be regulatory, impacting
- gene expression levels or which RNA isoforms are produced. Risk variants may impact splicing factor
- 59 60 binding leading to altered isoform splicing ratios [8]. For example, a risk variant block (rs1006737)
- within intron 3 of the SZ risk gene CACNAIC was linked to variable mRNA expression, while GADI 61
- 62 long and short isoform expression in hippocampus was associated with the SZ and ASD risk variant
- 63 (rs3749034) within the promoter [30, 31]. However, there is a current lack of understanding about
- how risk gene expression and splicing are altered by the risk variants and therefore profiling both their 64
- expression and RNA isoforms is essential to link genetic changes to disease pathophysiology. 65
- Current sequencing technologies including Illumina short-reads perform well at detecting novel AS, 66
- 67 however the lack of long-range exon connectivity information inherent in short-reads means these
- approaches are limited in their ability to identify and quantify full-length isoforms and this issue is 68
- exacerbated in longer, more complex genes [32, 33]. In contrast, long-read technologies including 69
- 70 Oxford Nanopore Technologies (ONT) and Pacific Biosciences (PacBio) can sequence entire
- 71 isoforms in a single read enabling more accurate isoform profiling [7, 34]. Such technologies now
- 72 make it feasible to comprehensively examine gene isoform profiles. Initial investigations of SNX19
- 73 and CACNA1C demonstrated the incomplete knowledge of isoform profiles in humans and the likely
- 74 importance of novel gene isoforms in disease risk [35, 36].
- 75 In this study we addressed the lack of knowledge surrounding MHD risk gene isoform expression
- 76 using nanopore amplicon sequencing. We developed a new bioinformatic tool, IsoLamp, to identify
- 77 known and novel RNA isoforms from long-read data. Analysis of the RNA splicing profiles of 31
- 78 MHD risk genes identified 363 novel RNA isoforms and 28 novel exons. We identified several genes
- 79 where most expression is from novel isoforms, including ATG13 and GATAD2A, where the most
- highly expressed isoforms were novel. Our results show the transcript structure for most risk genes is 80
- more complex than current annotations, containing additional exon skipping events, retained introns, 81
- novel splice sites and novel exons, including novel isoforms that alter the protein and potentially its 82



84 a role in disease pathophysiology.



86 **A**



90 Figure 1A. RNA isoform sequencing of human post-mortem brain. RNA was isolated from frontal cortical 91 regions, caudate (CAUD) and cerebellum (CBM) and converted to cDNA. The coding sequence (black boxes) 92 was amplified using specific forward (Fwd, yellow arrows) and reverse (Rvr, pink arrow) primers generally 93 designed in the 5' and 3' UTR regions (grey boxes) to capture as many isoforms as possible. An Oxford 94 Nanopore Technologies (ONT) adaptor sequence (blue box) was incorporated into each primer for sample 95 multiplexing. Samples were then barcoded and pooled to create a single library for long-read sequencing on a 96 GridION. Key: Brodmann Area (BA), barcode (BC), Oxford Nanopore Technologies (ONT). B. Isoform discovery 97 with long-read amplicon sequencing (IsoLamp) workflow. A gene specific parameters file (containing 98 chromosome and primer coordinates) was used to align long-reads for each sample (B1-3) against the 99 reference (black box) using Minimap2. Known and novel RNA isoforms were identified using Bambu. Identified 100 isoforms are then filtered (grey isoforms) to remove those not overlapping forward (yellow line) and reverse 101 (pink line) primer positions, ensuring full-length isoform discovery. Low expression (blue on heatmap) isoforms 102 were also filtered out as indicated by dashed red lines. Filtered known and novel isoforms can then be 103 annotated, quantified using IsoLamp output files and visualised using IsoVis.

105 **Results**

106 Experimental overview

107 To identify the RNA isoforms expressed from genes of interest, collated from GWAS evidence, we

- aimed to perform long-read amplicon sequencing, which provides a highly sensitive means for
- 109 comprehensive isoform discovery and relative quantification (Figure 1A, Supplementary Figure 1)
- 110 [35]. We selected seven regions of post-mortem human brain from five control individuals,
- encompassing both transcriptionally divergent regions as well as those highly implicated in MHDs
- 112 (Supplementary Table 1). Amplicons were designed cover the full coding region of target genes and,
- 113 where possible, run from the first to the last exon. Multiple set of primers were used for genes with
- alternative transcriptional initiation and termination exons and/or alternative coding sequence
- 115 initiation and termination sites.

116 IsoLamp: a tool for RNA isoform discovery from long-read amplicon sequencing

117 While there are several long-read isoform discovery and quantification tools, these are not generally

- 118 optimised for amplicon sequencing of single genes at high depth. Therefore, we created ISOform
- 119 discovery with Long-read AMPlicon sequencing (IsoLamp), a custom pipeline designed for isoform
- 120 profiling from amplicon sequencing (Figure 1B). In contrast to previous tools [35] IsoLamp can be
- applied to any gene, provides flexible filtering options and provides a simpler, unified, output of
- 122 isoforms.
- 123 We benchmarked the performance of IsoLamp using synthetic Spike-in RNA variants (SIRVs) that
- 124 provide a known ground truth for isoform exonic structures and abundances. We performed long-read
- amplicon sequencing on SIRV5 and SIRV6, targeting five isoforms per gene, as these SIRVs allowed
- targeting of the largest number of isoforms with a single primer pair and so best recapitulated human
- 127 genes. The SIRV dataset comprised nine replicates from each of the three SIRV mixes (E0, E1, E2)
- 128 for each gene (Supplementary Figure 2). 99% of reads mapped to the SIRV genome with minimap2
- 129 [37], confirming on-target amplification. We benchmarked the performance of IsoLamp with Bambu
- [38], FLAIR [39], FLAMES [40] and Stringtie2 (-L) [41]. We assessed the precision, recall and
- expression correlations of the five tools using three different reference annotations (Figure 2A-C,
- 132 Supplementary Figure 3, Supplementary Table 2): 1. Complete contains all SIRV isoforms, 2.
- 133 Insufficient missing SIRV isoforms known to be present, and **3.** Over contains additional isoforms
- that are not present in the SIRV mixes.
- 135 Our benchmarking results demonstrated IsoLamp had the highest precision and recall values,
- 136 consistently outperforming other isoform discovery tools by correctly identifying true isoforms and
- 137 minimising false positives (Figure 2A, Supplementary Table 2). This included maintaining high
- 138 performance with the more challenging, but also more realistic, insufficient and over annotation
- references. IsoLamp expression quantification was also consistently accurate and maintained
- 140 performance irrespective of the annotation provided (Figure 2B, C).
- 141 Bambu, which is also utilised within the IsoLamp pipeline, was the next best performing tool,
- 142 although it identified more false positives and had poorer recall and quantification results using the
- 143 insufficient annotation (Figure 2A-C). IsoLamp utilises Bambu parameters optimised for amplicon-
- sequencing, including a novel discovery rate (NDR) of 1. Adjusting the Bambu 'NDR' to 1 improved
- its recall but didn't improve precision (Figure 2A-C, Supplementary Table 2). These results
- 146 demonstrate how IsoLamp outperforms tools designed for whole-transcriptome analysis, including
- 147 when Bambu is provided with optimised isoform discovery parameters for amplicon sequencing.

148 FLAIR had the highest number of isoforms of all tools tested identifying 261, 181, and 278 novel transcripts in the complete, insufficient, and over-annotated reference-based analyses, respectively. This 149 150 high level of false-positive novel transcripts led to inaccuracies in transcript abundance assignments, 151 resulting in low correlations compared to other tools (Figure 2A-C). FLAMES exhibited 100% recall for SIRV5 across all annotations, however, its performance with SIRV6 was suboptimal, indicating a 152 higher degree of variability in the FLAMES isoform discovery pipeline. FLAMES also performed 153 154 poorly for isoform quantification. Lastly, while Stringtie2 did not introduce large numbers of false positives, it had the highest number of false negatives, including when provided with complete 155 156 annotations (Figure 2A-C, Supplementary Table 2).

157 IsoLamp employs an optimised expression-based filter to remove lowly expressed isoforms that are

158 likely to be false positive detections. Applying this filter to Bambu, FLAIR, and FLAMES

substantially reduced false positive novel isoforms and enhanced overall precision (Supplementary


160 Figure 3, Supplementary Table 2), though IsoLamp was still the top performing tool. Beyond

synthetic benchmarking data, reference annotations are typically a combination of insufficient and

162 over annotations. In such scenarios, IsoLamp demonstrated better or comparable correlations with all

other tools (Figure 1A-C, Supplementary Figure 3), suggesting its superiority for amplicon sequencing based isoform discovery and quantification from real biological data.

165



166

Figure 2. Benchmarking IsoLamp using spike-in SIRVs. A. Precision recall of each tested pipeline with the
 complete, insufficient or over annotated SIRV reference. IsoLamp (black) returned high quality isoforms from
 amplicon data of both SIRV5 and 6. Pearson (B) and Spearman (C) correlations for each pipeline between

170 known and observed expression values for SIRV 5 and 6 mixes.


171 Post-mortem human brain RNA quantity and quality

- 172 Total RNA for long-range amplicon sequencing was extracted from 7 brain regions from 5 healthy
- individuals (Ind01 05) and subject to sample QC (Supplementary Figure 4A-D). RINe (mean = 7.4,
- 174 range = 6 8.1) did not differ by brain region, however Ind04 had significantly lower RINe scores
- 175 (Supplementary Figure 4B). No trend between the PMI (mean = 44.25 hrs) and RINe was observed
- 176 (Supplementary Figure 4C). RINe appeared to worsen with decreasing brain tissue pH levels
- 177 (Supplementary Figure 4D). A principal component analysis (PCA) showed separation of Ind04
- 178 (likely driven by lower sample pH and RINe) and of cerebellum and caudate samples from cortical
- regions in PC1 and PC2 (Supplementary Figure 5AB). A relatively small proportion of variance
- 180 (4.7%) was attributed to control donor age in PC6 (Supplementary Figure 5C).

181 Long read sequencing identifies 363 novel RNA isoforms

- 182 A total of 31 risk genes were selected for amplicon sequencing based on the accumulated evidence for
- their involvement in neuropsychiatric disorder risk. A custom database of risk genes and their
- 184 evidence levels was created and genes ranked (Methods). In a reflection of current GWAS cohort
- sizes, 21 of the selected genes had the highest evidence for involvement in risk for SZ, 7 for MDD, 2
- 186 for ASD and 1 for BPD (Figure 3A). Evidence from GWAS, TWAS and other studies show that some
- 187 genes appear to be risk factors for multiple disorders including *KLC1* for SZ, MDD and ASD (Figure
- 188 3B).
- 189 The full RNA isoform profile for each gene was sequenced using nanopore long-read amplicon
- sequencing. Mapping accuracy ranged from 93.7% (*CLCN3*) to 97.5% (*SORCS3*) (Supplementary
- 191 Figure 6A, B). Each novel isoform and its predicted impact on known protein domains, open reading
- 192 frame (ORF) and associated instability index was recorded (Additional File 1) and visualised using
- 193 IsoVis (Additional File 2) (Wan et al., 2024, *under review*). With no TPM filter set in IsoLamp we
- 194 identified 872 known and novel isoforms across all 31 neuropsychiatric disorder risk genes. To filter
- this list for more highly expressed novel isoforms we applied a TPM filter which resulted in 441
- 196 known and novel isoforms across all genes (Figure 4A). Of these, SQANTI [42] classified 78 as
- 197 known (full splice match (FSM)), 256 as novel but using known splice sites or junctions (novel in
- catalogue (NIC)), and 107 as containing at least one novel splice site (novel not in catalogue (NNC))
- 199 (Figure 4A).
- 200 We next asked what proportion of reads for each gene were assigned to novel isoforms (Figure 4B).
- 201 This ranged widely from approximately 96.9% for *GATAD2A* to 0% for *GRIN2A*, which was the only
- 202 gene for which no novel RNA isoforms were detected. Approximately one quarter (7/31) of genes
- 203 investigated had most of their gene expression assigned to novel isoforms, demonstrating how
- isoforms and their expression profiles for many genes are still poorly understood. As our amplicon-
- sequencing does not encompass all variations in transcriptional initiation and termination sites, these
- results can be seen as a lower bound for the number of novel isoforms. Linear regression of gene
- 207 isoform counts (Supplementary Figure 7) and novel isoform proportion did not reveal a significant
- 208 relationship with amplicon length or canonical exon count, indicating that detection of novel isoforms
- 209 is largely gene dependent (Supplementary Figure 8A-D). To determine what was different about the
- splicing pattern of each novel isoform we further sub-classified them using SQANTI, based on the use
- of a combination of known exon junctions (COJ) or splice sites (COS), retained intron (RI) or
- containing at least one novel splice site (ALO) (donor, acceptor or pair) [42]. Overall, the most reads
- 213 were assigned to "novel combination of known junctions", where all individual exon combination
- 214 were known but the entire chain of exons was novel. The type and proportion of novel isoforms from

each category was highly gene specific, demonstrating a wide variety of novel RNA types missing







Figure 3. Selection of high-confidence MHD risk genes for amplicon sequencing. A. Risk genes included in this
 study classified by the disorder for which they have the highest evidence of association. B. Sequenced genes
 and their evidence levels for each MHD. The evidence count was calculated as the sum of independent analysis

types for example, GWAS, MAGMA, TWAS, SMR, DNA methylation, fine mapping, protein-protein interaction

- and targeted validation studies, that supported gene involvement in risk for a particular disorder. [#]Indicates re-
- 228 sequencing of a gene from a previous study (Clark *et al.* 2019).

230 A




Total = 441

В


_ _ _





234

С



236 Figure 4. A. The total number of known and novel isoforms identified across all 31 risk genes. SQANTI

- 237 structural categories are known/full splice match (FSM), novel in catalogue (NIC) and novel not in catalogue
- 238 (NNC). **B.** Proportion of reads (reported as transcript per million, TPM) for each gene as classified by the
- 239 SQANTI sub-category. C. Count of predicted outcomes for novel isoform subcategories. Expasy [55] was used
- to examine the open reading frame (ORF) of novel isoforms (SQANTI structural category: novel not in
- catalogue (NNC) or novel in catalogue (NIC)) using the canonical start and stop as a reference. Predictions were
- categorised as coding if the ORF was retained, nonsense mediated decay (NMD) if a premature termination
- codon was present and not within 50 nt of the final exon junction or unknown (unkn) if there was not enough
 information. Novel isoform SQANTI subcategories (subcat) are, at least one novel splice site (ALO), intron
- retention (IR) and combination of known junctions (COJ) or splice sites (COS).
- 246
- _____
- The impact of each novel isoform on the encoded ORF was examined using Expasy [43] and recordedas retaining the canonical or other known reading frame (coding), likely-NMD or unknown. Novel
- isoforms were classified as coding for 54.2%, 67.3% and 75.4% for ALO, COJ and COS
- subcategories respectively. We identified 49 novel isoforms that contained retained introns, 39 (83%)
- of which were predicted to lead to NMD (Figure 4C). Our results were also useful for several genes in
- identifying the probable isoforms represented by GENCODE transcript fragments. For the SZ risk
- 253 gene clusterin (*CLU*), the novel Tx1 (COJ) extended ENST00000520796 to the canonical stop codon
- and suggested this isoform is moderately abundant (8.2% of TPM) across all brain tissues. The ASD
- risk gene microtubule associated protein tau (*MAPT*) novel Tx5 extended ENST00000703977 and
- further demonstrated that inclusion of canonical exon 7 (chr17:45,989,878-45,990,075) does not
- always exhibit coordinated splicing with canonical exon 5. This isoform had moderate expression
- comprising 3.2% of *MAPT* TPM.
- 259 Isoforms that contained 'at least one novel splice site' (ALO) generally contained a novel deletion
- 260 within a known exon or had novel donors and/or acceptors. All novel junctions in ALO isoforms were
- 261 canonical GT-AG, GC-AG or AT-AC junction pairs, though often only the splice donor (GT) or
- acceptor (AG) was novel, for example a novel splice acceptor (+98 nt) for *CPT1C* exon 17
- 263 (Supplementary Figure 9A, B). We found that ~48% of ALO isoforms contained either a single novel
- splice donor or acceptor. Novel GC-AG pairing was detected in two SZ risk genes, within the 5'UTR
- of *GABBR2* and the donor site of a validated novel exon in *RFTN2*. These results show a clear
- advantage of using long-read sequencing to contextualise novel splice sites which aids in predicting
- the outcome on the isoform and ORF.

268 Detection of highly expressed novel isoforms

- 269 A key question regarding novel isoforms is whether they are expressed at high enough level to impact
- 270 the biological function of a gene. This is a complex question, because a novel isoform could be low at
- the tissue level but highly abundant in a specific cell type, or multiple expressed novel isoforms can
- be significant cumulatively, especially if they all encode the same change to a protein. Therefore, we
- focused on genes with significant individual or cumulative expression of novel isoforms (analysis on
- all gene isoforms is available in Additional File 2).
- 275 We identified 22 novel isoforms for the schizophrenia risk gene autophagy-related protein 13
- 276 (*ATG13*). Novel isoforms represented 64% of gene expression, compared to 36% for full-splice
- 277 matches. The most abundant class of novel isoforms (15/22) were COJ, which made up 55.4% of gene
- expression (Figure 4B). *ATG13* had two alternative splicing hotspots, firstly with the 5'UTR and
- secondly around a predicted disordered region involving exons 12 and 13 in the canonical isoform.
- Across all brain regions the most highly expressed isoform was the novel COJ transcript 26 (Tx26),


which represented 23% of TPM, surpassing the canonical transcript ENST00000683050 (12.8%).


- 282 Tx26 differs from the canonical transcript by skipping of exon 12 (Figure 5A, B). It contains the same
- 283 CDS as ENST00000359513 but includes an additional exon in the 5'UTR (exon 3). Novel COJ
- transcripts 6 and 8 also had high TPMs and together accounted for 16.6% of expression. These
 isoforms were novel due to a combination of 5'UTR exons not previously seen within full-length
- **286** GENCODE annotations.

The schizophrenia risk gene CUB and sushi multiple domains 1 (*CSMD1*) was the longest CDS we amplified at approximately 10,838 nt encompassing 70 coding exons. In total, 8/9 detected isoforms

- were classified as novel (Additional File 2I). Following the canonical isoform (ENST00000635120,
 51.5% of TPM), novel transcripts 26 (COJ) and 33 (ALO) accounted for 38.3% and 7.1% of isoform
- 291 TPMs, respectively (Figure 5C, D). Novel Tx26 skipped known exon 65 which encodes a sushi 28
- extracellular domain and glycosylation site. The ORF of Tx26 retained the reading frame encoding a
- 293 3549 amino acid (aa) protein. Novel Tx33 contained a novel splice donor (GT, -8 nt) in canonical
- exon 21 and was predicted to encode a PTC in canonical exon 22. The full Tx33 mRNA also skipped
- canonical exon 65. *CSMD1* also provides a useful example of the benefit of long read for profiling
- 296 isoforms. GTEx isoform expression data (<u>https://www.gtexportal.org/home/gene/CSMD1</u>) for
- 297 *CSMD1* in brain is almost exclusively assigned to isoforms with downstream transcriptional initiation
- sites (including the two-exon fragment ENST00000521646), despite splice junction level expression
- 299 largely supporting expression from the canonical start site. This emphasises the difficulty of
- assembling and quantification expression of full-length isoforms from long, complex genes, which
- 301 can be achieved using long isoform spanning reads.
- 302 The chromatin remodelling subunit and shared SZ and BPD risk gene GATA zinc finger domain
- 303 containing 2A (*GATAD2A*) had one of the highest proportions of reads (96.9%) assigned to novel
- 304 isoforms (Additional File 2N). Most novel isoforms were predicted to be coding COJs (10/24) and
- these also accounted for the majority of novel expression (66.6%). Novel Tx17 had the highest
- 306 expression level (22.7%) of any *GATAD2A* isoform and skipped canonical exon 10 which overlaps a
- 307 CpG island (212 nt, 21.7% CpG) and contains a disordered, polar residue biased region and a
- 308 phosphorylation site (Figure 5E). Two additional novel isoforms (Txs 8 and 12), together accounting
- 309 for 19.9% of expression, incorporated a known 89 nt 5'UTR exon (ENST00000494516) into full-
- 310 length isoforms for the first time, clarifying the isoforms expressed from this gene. It is important to
- note that there are two known start sites for this gene supported by high levels of CAGE reads and
- human mRNA. The forward primer used in this study was located within the 5'UTR of
- ENST00000360315 and as such expression levels of alternatively spliced isoforms from
- ENST00000683918 are not included in this analysis (Supplementary Table 3).
- Several additional genes had relatively high levels of at least one novel isoform including the SZ risk genes kinesin light chain 1 (*KLC1*), protein tyrosine kinase 2 beta (*PTK2B*) and protein arginine
- methyltransferase 7 (*PRMT7*). *KLC1* novel transcript 1, 31.4% of gene TPM, was predicted to retain
- the canonical ORF and included a known (ENST00000380038) splice acceptor (+75 nt) with an
- alternative 3' end (Additional File 2S). *PTK2B* novel transcripts 25 and 11 together accounted for
- $\sim 42\%$ of total expression and both had variable splicing, including a novel donor (GT, +141nt), of the
- 5'UTR exon 5 (ENST00000519650) (Additional File 2Y). *PRMT7* novel transcript 18, 12.3% of
- 322 TPM, skips canonical exon 4 which may lead to NMD or alternatively, use a supported
- 323 (ENST00000686053) translation start site in the following exon (Additional File 2X).
- The full RNA isoform profile for the SZ risk gene calcium voltage-gated channel subunit alpha1 C
- 325 (*CACNA1C*) has previously been reported and was repeated in this study [35]. In total, we identified 5

- annotated and 22 novel isoforms. The most highly expressed novel isoform identified in our previous
- study, 'novel 2199', now known as ENST00000682835.1 was also identified in our samples and
- 328 exhibited similar cerebellar specific expression. Importantly, 10 novel isoforms replicated one of two
- alternative splicing events in a hotspot identified previously in canonical exon 7 [35]. This hotspot
- contains the canonical splice site and two alternative 3'SS acceptors over only 12 nucleotides (chr12:
- 331 2,493,190-2,493,201) (Supplementary Figure 10).





345

346 Figure 5. Highly abundant novel isoforms and the predicted mRNA outcome. (A,C,E) mRNA splice graphs. 347 Dark and light grey boxes indicate 5' and 3' UTR and coding exons respectively. Numbers indicate the coding 348 exon of interest. Orange arcs (pre-mRNA) and boxes (mRNA) indicate novel splicing events. mRNA isoforms 349 depict known isoforms (ENST) against novel (Tx) isoforms, ".." indicates abbreviated zeroes. (B,D) IsoVis 350 visualisation of isoform structures (centre stack) and expression levels (heatmap). Canonical isoform shown at 351 top of stack including exonic mapping of protein domains (purple) and disordered regions (green) A. Splice 352 graph of ATG13 highlights the open reading frame (ORF) preserving skipping event of canonical exon 12. B. 353 High expression of ATG13 novel transcript 26 (Tx26). C. Splice graphs highlighting novel changes in CSMD1 354 novel transcript 26 (Tx26) and 33 (Tx33) within highlighted pink regions. The ORF retaining skipping event of 355 canonical exon 65 may disrupt a known glycosylation site (black bar), a sushi domain extending from exon 64 356 (blue) and part of an extracellular domain (green). Tx33 contains a novel splice donor (-8 nt) within exon 21 357 leading to a premature termination codon (PTC) in exon 22. Dashed lines indicate continuation of the 358 transcript to 5' or 3' coding exons. D. Relatively high expression of CSMD1 novel transcripts 26 and 33. E. 359 GATAD2A novel transcript Tx17 contained a novel, ORF retaining, skipping event of canonical exon 10 which 360 contains a phosphorylation site (black bar), part of a polar biased region (blue) and overlaps a CpG island (<300 361 bp, green). Dashed lines indicate alternative splicing of 5'UTR exons.

362

363 Novel isoforms alter predicted protein structures

Novel isoforms have the potential to affect either post-transcriptional regulation and/or protein
sequence, structure and function. We next investigated a selection of isoforms that would be predicted
to lead to protein changes to understand their possible impact.

- 367 Several novel isoforms (including 5 of the top 20 by expression, Additional File 2R) predicted a novel
 368 exon 22 skipping event in the SZ and MDD risk gene *ITIH4*. Targeted mass spectrophotometry
- 369 confirmed a novel junction between exons 21 and 23 (ETLFSVMPG//PVLPGGALGISSSIR) created
- due to skipping of exon 22 (Figure 6A, Supplementary Figure 11). This event was predicted to encode
- a PTC <50 nt from the final exon junction, indicating it may not be directed to NMD. Protein
- 372 structure prediction of the canonical (ENST00000266041.9) and a representative novel isoform
- 373 (Tx71) indicated a loss of 106 aa (\sim 44%) of the 35 kDa heavy chain domain but retention of three O-
- 374 glycosylation sites (Thr:719, 720, 722) (Figure 6B-D). Novel transcript 71 accounted for ~3.7% of
- 375 *ITIH4* TPM and this skipping event was found in an additional 24/68 (~35%) novel isoforms which
- together accounted for 23.4% of TPM. Tx71 also skipped canonical exons 15 and 16, which contain a
 protease susceptibility region (residues 633 713) and a MASP-1 cleavage site (645 646: RR) [44].
- 378 Cleavage at this site and subsequent formation of an ITIH4-MASP complex can inhibit complement
- activation via the lectin pathway [44]. However, skipping of canonical exon 22 was not mutually
- inclusive with skipping of exons 15/16 as other novel isoforms with exon 22 skipping retained exons
- 381 15/16. The absence of much of the 35 kDa heavy chain domain is likely to impact on ITIH4 protein
- function and further studies will be required to examine if it plays a role in neuronal phenotypes.
- Ten novel isoforms were identified for the SZ risk gene glutamate metabotropic receptor 3 (*GRM3*).
 Three novel isoforms (Txs 6, 7, 9) skip exon 2 which contains the canonical translation start site and

385 instead could use an alternative, frame retaining, translation initiation site in exon 1, extending the

- truncated reference isoform ENST00000454217.1 which is also supported by human amygdala 386
- mRNA (AK294178) (Additional File 2Q). Translation of these isoforms would likely cause 387
- significant disruption to the resultant protein with removal of the signal peptide, transmembrane 388 domain and disulphide bonds. Cumulatively these novel isoforms accounted for a relatively low 8.8% 389
- 390 of expression when compared to the canonical isoform (86.5%).

Both novel isoforms and exons were identified for the shared MDD and ASD risk gene neuronal 391 392 growth regulator 1 (NEGR1). Most reads (83.5%) were assigned to the canonical NEGR1 isoform 393 (ENST00000357731, 354 aa). Three novel isoforms were identified, two of which (Txs 1 and 2) contained novel exons (Figure 7A, B). These transcripts accounted for 9.4% (Tx2) and 5.1% (Tx1) of 394 TPM. Both novel exons were located between cassette exons 6 - 7 and were validated using Sanger 395 396 sequencing. The novel exon within Tx1 was 42 nt (14 aa) in length, had high 100 vertebrate 397 conservation (UCSC) and was predicted to be frame retaining (Supplementary Figure 12A). Protein 398 structure prediction of the 368 aa Tx1 using AlphaFold [45] showed a 14 aa extension near the Cterminal prior between the GPI anchor (G:324 aa) and the three immunoglobulin-like domains 399 400 (Supplementary Figure 12B). In contrast, the 58 nt novel exon within Tx2 encoded a PTC (TAG) only 35 nt distant to the final exon junction complex, suggesting it might not trigger NMD. Truncation of 401

- the protein at this position (313 + 7 novel aa) would remove the GPI anchor potentially creating a near 402
- complete protein (320 aa) that is unable to attach to the cell membrane (Supplementary Figure 12C). 403


404

Brain region specific expression of novel isoforms 405

Many isoforms have brain region enriched or specific expression [46, 47]. Our amplicon sequencing 406 approach identifies the presence and relative expression proportion of different isoforms. We next 407

- 408 asked if any novel risk genes isoforms showed expression differences between brain regions. Overall, cerebellum exhibited most differences in isoform expression, consistent with previous whole 409
- transcriptome results [12]. 410
- Depression risk gene DCC netrin 1 receptor (DCC) novel isoform Tx9 had significantly higher TPM 411 in cerebellum (Figure 8A, Additional File 2J). TPMs of Tx9 in CBM were approximately 10x higher 412
- than the average for cortical regions and 3x higher than in caudate. This isoform, classified as a COJ 413
- 414 and predicted to encode a 1425 as protein, accounted for \sim 5% of total DCC expression. Tx9 uses an
- 415 alternative 3'SS (-60 nt) in cassette exon 17 and the skipped nucleotides cover an extracellular region
- 416 and fibronectin type-III domain (UniProt). The SZ risk gene double C2 domain alpha (DOC2A) had
- two novel isoforms with significant variation in brain specific expression including Tx8 in cerebellum 417
- and Tx53 in caudate (Figure 8B, C, Additional File 2K). Novel Tx8 used a novel splice donor in 418
- 419 canonical 5'UTR exon 1 (GT, +158 nt) and was predicted to encode a 400 aa protein unchanged from the canonical transcript. Tx53 was the only novel transcript that showed moderate but specific 420
- 421 expression in caudate samples or any tissue other than cerebellum. Tx53 extends the known isoform
- 422 ENST00000574405 to the canonical stop and is predicted to encode a 400 aa protein. Overall, 28
- novel isoforms in 11 risk genes were found to have variable expression amongst brain tissues 423
- supporting a role for these isoforms within specific brain regions or potentially in a subset of cells. 424

426



445 Figure 6. ITIH4 canonical and novel isoform protein structure predictions. A. IsoVis stack of the top seven 446 ITIH4 isoforms sorted by expression. Several novel isoforms contained the novel exon 22 skipping event (red 447 box) including Txs71 and 94. B. Canonical isoform (ENST00000266041, UniProt:Q14624) structure prediction 448 indicating 70 kDa (orange) and 30 kDA (blue) chains C. Novel isoform (Tx71) structure prediction indicating 70 449 kDa chain (orange), truncated 30 kDA chain (blue), O-glycosylation sites (green), novel splice junction peptide 450 detected using mass spectrophotometry (red) and novel peptides (pink). Black arrow indicates termination <50 451 nt from the final exon junction complex. D. AlphaFold per-residue confidence scores (pLDDT) (0-100) for ITIH4

452 novel transcript 71: very high (>90, blue), confident (90-70, light-blue), low (70>50, yellow) and very low (<50,
453 orange).

454 Sequencing and validation of novel exons


455 Our amplicon sequencing approach detected a total of 28 novel exons in 13 MHD risk genes. Using

- 456 RT-PCR followed by Sanger sequencing we validated a set of 21/21 targeted novel exons (Table 1).
- 457 The SZ risk gene chloride voltage-gated channel 3 (CLCN3) contained four novel exons within six
- 458 novel isoforms, and an example of PCR validation is shown in Supplementary Figure 13A. Validated
- novel exon mean length was 99 nt, ranging from 41 nt (*CLCN3*) to 231 nt (*GRM3*). 16 (76%) of
- validated novel exons were classified as 'poison exons' as they encoded a PTC (Supplementary
- 461 Figure 13B), although two of these poison exons, within *NEGR1* and *XRN2*, were <50 nt from the
- final exon junction and therefore may not undergo NMD. The novel exon contained within Tx3 for
- 463 *XRN2* had the second highest isoform expression for the gene, following the canonical transcript
- 464 (ENST0000037191), with 4.7% of TPM. If translated, this transcript would omit an omega-N-
- 465 methylarginine modification site (ARG:946) within a disordered region at the C-terminus
- 466 (Supplementary Figure 14, Additional File 2AE).
- 467 Three novel exons were in untranslated regions and two were predicted to retain the ORF, including
- the 42 nt exon in *NEGR1* mentioned previously and a 60 nt exon within *SORCS3*. *SORCS3* is a
- 469 member of the VPS10 transmembrane protein family and assists with neuronal protein trafficking and

sorting and a lack of *SORCS3* in the hippocampus in mice has been associated with impaired learning

and fear memory in mice [48-50]. The novel exon in Tx1, encoding 20 aa

- 472 (AMCGRAQWFTPVILALWETE), falls within the *SORCS3* lumenal region (position:
- 473 LYS:956/PRO:957) and did not appear to disrupt the transmembrane or cytoplasmic domains.
- 474 Comparison of protein prediction models of the canonical (ENST00000369701.8) and novel isoform
- (Tx1) showed the addition of an unstructured loop with a partial alpha helix within the second
- 476 polycystic kidney disease (PKD2) domain (Figure 8A-D), though the prediction confidence was low,
- so the structural impact on the PKD2 domain remains uncertain [51].



483

484 Figure 7. NEGR1 splice isoforms in human brain. A. NEGR1 mRNA splice graph highlighting validated novel 485 exons 6a and 6b. Dark and light grey boxes indicate 5' and 3' UTR and coding exons respectively. Numbers 486 indicate the coding exon of interest. Orange arcs (pre-mRNA) and boxes (mRNA) indicate novel splicing 487 events/exons. mRNA isoforms depict known isoforms (ENST) against novel (Tx) isoforms, ".." indicates 488 abbreviated zeroes. In the open reading frame (ORF) retaining Tx1, a GPI anchor (red line) is shown to shift 3' 489 in the final exon when compared to ENST00000357731. Tx2 encodes a premature termination codon (PTC) 490 within the novel exon. B. IsoVis visualisation of NEGR1 isoform structures (centre stack) and expression levels 491 grouped by brain region (heatmap). Canonical isoform shown at top of stack including exonic mapping of a 5' 492 signal peptide (brown) and three immunoglobulin (Ig)-like domains (purple). Canonical 3'UTR has been 493 trimmed.




Figure 8. Brain region specific expression of novel isoforms. A. *DCC* novel transcript 9 (Tx9) uses a known
(ENST00000581580) alternative 3'SS (-60 nt) in cassette exon 17 and had significantly higher TPM in CBM.
ANOVA: F=9.098, DF=28. B-C. *DOC2A* novel transcripts. Tx8 used a novel splice donor in canonical 5'UTR exon
1 (GT, +158 nt). ANOVA: F=20.73, DF=28. Tx53 extended the known reference isoform ENST00000574405 to
the canonical translational stop and had significantly higher TPM in caudate. ANOVA: F=8.261, DF=28.
Brodmann's Area (BA), caudate (CAUD), cerebellum (CBM) and temporal cortex (TCX). Ordinary one-way

506 ANOVA Tukey's multiple comparison adjusted P value: **= $P \le 0.01$, ***= $P \le 0.001$, ****= $P \le 0.0001$.

Table 1. Neuropsychiatric disorder risk gene novel exon val

	Novel	Novel Genomic coordinates			Size		UniProt/Pfam
Gene	exon	Chr	Start	End	(nt)	Classification	domain
SORCS3	20a	10	105244778	105244837	60	ORF	Lumenal
GRIA1	2a	5	153509750	153509806	57	PTC	Extracellular
XRN2	16a	20	21345834	21345887	54	PTC	None
XRN2	29a	20	21387308	21387371	64	PTC (<50nt)	Disordered
SLC30A9	6a	4	42028140	42028260	121	PTC	Helix
SLC30A9	9a	4	42059964	42060036	73	PTC	Cation efflux family
GRM3	2a	7	86776784	86777014	231	PTC	None
GRM3	3a	7	86832296	86832411	116	PTC	None
NEGR1	6a	1	71532866	71532907	42	ORF	None
NEGR1	6b	1	71587343	71587400	58	PTC (<50nt)	Transmembrane
RFTN2	1a	2	197654257	197654391	135	PTC	None
RFTN2	1b	2	197671542	197671664	123	PTC	None
RFTN2	6a	2	197616952	197617073	122	PTC	None
CNTN4	1a	3	2656485	2656587	103	PTC	None
PTK2B	3a	8	27318676	27318793	118	UTR	None
PTK2B	3a (short)	8	27318696	27318793	98	UTR	None
PTK2B	3b	8	27319918	27319985	68	UTR	None
CLCN3	1a	4	169630165	169630335	171	UTR	None
CLCN3	2a	4	169638597	169638742	146	PTC	Cytoplasmic
CLCN3	2b	4	169640168	169640208	41	PTC	Cytoplasmic
CLCN3	2c	4	169663527	169663617	91	PTC	Cytoplasmic

<u>Definitions</u>: chromosome (Chr), nucleotide (nt), open reading frame (ORF), premature termination codon (PTC), untranslated region (UTR).

508 Discussion

- 509 In this study we used long-read sequencing to profile 31 neuropsychiatric disorder risk genes
- 510 identifying 363 novel RNA isoforms. We also present a new bioinformatic tool, IsoLamp, that can
- 511 accurately identify and quantify novel RNA isoforms from long-read amplicon data. The recent
- 512 proliferation of GWAS studies examining increasingly large population-wide data has identified
- 513 hundreds of genomic variants associated with risk of developing a mental health disorder [23, 52].
- 514 Evidence suggests that some risk variants, specifically those that are non-coding, play a role in pre-
- 515 mRNA splicing and our current understanding of the transcriptomic profile for these risk genes is
- 516 limited [35, 53]. A key finding of our research is both the high number of novel expressed RNA
- 517 isoforms and, for some risk genes, the high expression of novel isoforms both individually and
- 518 collectively. This finding reflects both the known complexity of alternative splicing in the human
- 519 brain [54] and the current incompleteness of the reference transcriptome. As a result of the relatively
- 520 deep sequencing afforded by this long-read approach, we have shown that there is a much higher level
- 521 of RNA isoform diversity for these genes than reported in the current reference annotations. These
- 522 findings provide new insight into the repertoire of RNA isoforms expressed in brain that could be
- 523 important for understanding the risk and onset of neuropsychiatric disorders.

524 RNA isoform discovery, classification and visualisation

- 525 We generated a set of high-confidence RNA isoforms from nanopore long-read data using IsoLamp.
- 526 IsoLamp optimises and streamlines transcript identification, quantification and annotation from long-
- 527 read amplicon data and outperformed other methods. IsoLamp improves upon our previously
- 528 published pipeline TAQLoRe [35] by expanding analysis capabilities to any gene and identifying all
- 529 isoforms within a single pipeline. Our overall approach also overcomes the significant challenge of re-
- assembling and classifying RNA isoforms using short reads [55-57]. The primary outputs from
- 531 IsoLamp, filtered transcripts (GTF) and transcript expression (TPM) is designed to be compatible
- with multiple downstream tools, including our visualisation tool IsoVis (https://isomix.org/isovis)
- 533 (Wan et al., 2024, *under review*).
- 534 Taken together, our benchmarking results highlight that IsoLamp's optimised isoform discovery
- parameters, coupled with its specific filters (expression, overlapping primers, and full-length reads),
- 536 yield significant improvements in both precision and recall compared to Bambu, FLAIR, FLAMES
- and StringTie2. The TPM filter applied to the data presented in this study is conservative and for long
- and complex genes may need to be tested to yield a balance of novel isoform detection and acceptable
- 539 expression levels. IsoLamp also output consistent expression quantification that was robust to the
- 540 quality of the annotations provided.

541 Novel RNA isoforms in neuropsychiatric disorders

- 542 The results presented in this study confirm our current limited understanding of RNA isoform profiles
- 543 in the human brain and demonstrates how long-read sequencing is a powerful tool to address this
- 544 issue [34, 35, 58].
- 545 We identified several highly abundant novel isoforms, including one, *ATG13* (Tx26), that was the
- 546 most abundant gene isoform. *ATG13* forms part of a protein complex, including ULK1 and FIP200,
- that is critical for autophagy [59]. In our samples, transcript 26 had the highest TPM and contained a
- 548 known skipping event of canonical (ENST000006683050) exon 12 which may be involved with
- 549 FIP200 binding and subsequent function of ATG13 [60]. Where Tx26 and several other novel
- 550 isoforms differ from known (e.g. ENST00000359513) isoforms is in the 5'UTR, indicating this region
- 551 may play a role in translation regulation [61]. Similarly, the SZ risk gene *CSMD1*, had relatively high

552 expression of novel isoforms. Recent evidence suggests enrichment of CSMD1 protein in the brain and activity as an inhibitor of the complement pathway in neurons [62]. Baum et al. (2024) show that 553 CSMD1 localises to synapses and that loss of CSMD1 can lead to increased complement deposition 554 potentially disrupting complement associated synaptic pruning. The novel isoforms identified in our 555 samples provide transcriptional pathways through which CSMD1 may be altered, potentially reducing 556 expression or function of the protein, for example through incorporation of a premature termination 557 codon (Tx33). Evidence from Alzheimer's disease studies has also linked increased complement 558 559 pathway activity to cognitive impairment, however further studies, particularly in human models of neuronal development will be needed to link CSMD1 transcriptional variability to SZ risk and severity 560 [62, 63]. KLC1 encodes one of the two light chains required for the microtubule motor protein 561 562 kinesin, mutations in which have previously been found in SZ patients and which resulted in a SZ-like phenotype in mice [64]. Novel KLC1 Tx1 (~31% TPM) was predicted to alter the C-terminal end of 563 the protein, an area known to undergo alternative splicing to expand cargo binding diversity [65]. The 564 combination of an altered C-terminal tetratricopeptide repeat (TPR), 3'UTR and relatively high 565 expression suggests novel Tx1 plays a role in brain, though the functional impact on the protein 566 requires further validation. 567

Several novel isoforms and exons were identified for the ion homeostasis and channel genes CLCN3, 568 CACNA1C and SLC30A9 which have shared risk for SZ, BPD and ASD [21, 23, 52]. Voltage-gated 569 570 ion channels are widely distributed in the brain and regulate neuronal firing. Mutations to these genes have been associated with disease and the emerging role of these channels in neuropsychiatric 571 disorders has been previously reviewed [66]. CLCN3 belongs to the CLC family of anion channels 572 573 and transporters and has an established role in human neurodevelopment [67, 68]. We identified and 574 validated four novel exons in CLCN3, three of which were predicted to encode a PTC which could 575 lead to NMD. The fourth was located within the 5'UTR, an area known to impact translation regulation in humans potentially through structural interference with the ribosome [61]. Splice 576

- variants of *CLCNC3* have been shown to impact intracellular localisation and our results identified
 additional splice variants, in particular a novel RNA isoform (Tx9) which is similar to
- 579 ENST0000613795, but includes a 76 bp exon 12 [67]. Twenty-two novel isoforms were identified for
- calcium channel gene *CACNA1C* and supporting previous findings [35] the top ten novel isoforms, by
- 581 TPM, were classified as frame retaining, supporting their potential to generate functional proteins.
- 582 *SLC30A9* (first known as *HUEL*) encodes the zinc transporter protein 9 (ZnT9), which is involved in
- zinc transport and homeostasis in the endoplasmic reticulum [69]. Whilst the function of the protein is
- not fully understood, a 3 nt familial deletion (c.1047_1049delGCA) in the highly conserved cation
- efflux domain (CED) has been recorded to result in changes to protein structure, intracellular zinc
- 586 levels and intellectual disability [70, 71]. Critically, we identified and validated a novel exon (Tx3-
- 587 9a:73 nt) within this CED providing evidence that this region may be alternatively spliced more
- 588 commonly than previously understood, potentially impacting protein function [69].
- 589 Finally, using mass spectrophotometry we confirmed a novel skipping event in the ITIH4 protein,
- indicating the utility of combining long-read sequencing with proteomics. ITIH4 is an acute-phase
- 591 protein the serum levels of which have been associated with MDD and is thought to be involved in
- neuro-inflammation [72, 73]. Despite several studies outlining an association for *ITIH4* and risk for
- 593 SZ, BPD or MDD onset, the causal mechanisms for this gene remain elusive and a further study is
- required to further explore the impact of the coding change detected in our study.

595 Limitations and future directions

- 596 Long-read amplicon sequencing, while providing an extremely sensitive isoform quantification
- 597 method, is limited by the set(s) of primers used to amplify each risk gene. Our method aimed to locate
- 598 primers within the 5' and 3' UTRs in proximity to the canonical translational start and stop codons.
- 599 This approach generally amplified the entire coding sequence but does not capture full-length
- 600 isoforms or variation in the UTRs and additional primers must be made to capture alternative unique
- start and termination sites. When using this method users must interpret the reported novel isoform
- proportions in the context of the known isoforms targeted e.g. if the canonical isoform is not a target
- 603 of the primer pair, novel isoform expression may appear inflated.
- 604 The results of our study are limited by the sample size of available control post-mortem brain tissue.
- 605 The nanopore long-read data for each risk gene was generated from five elderly, male control
- 606 individuals, with a single female sample removed from further analyses due to quality constraints.
- 607 The small number of available individuals means this dataset was not powered to investigate genotype
- 608 impacts on isoform expression, though this will be an important area of investigation to determine
- 609 which risk genotypes act through changes in isoform structure and/or expression.
- 610 Sample and RNA quality, as measured by RINe, is critical to high-quality sequencing and this is
- 611 especially true for long reads [35, 74]. Supporting previous findings in mRNA, our data suggest that
- 612 pH values <6.3 impacted the quality of post-mortem human brain RNA, which is especially critical
- 613 for robust amplification of longer (>5 Kb) CDS [75]. In general, PCR cycling was kept as low as
- 614 possible to avoid PCR bias towards shorter isoforms and other artifacts. However, we noted that lower
- 615 RINs, as recorded for Ind04, appeared to impact amplicons of longer CDS. To help overcome such
- 616 issues, future long-read amplicon sequencing could incorporate unique molecular identifiers to tag
- molecules prior to PCR to ensure an accurate representation of the original RNA isoforms [76].
- 618 The risk genes profiled in this study were selected based on multiple levels of evidence for their
- 619 involvement in risk, not only from GWAS but from meta-analyses and further independent studies
- 620 [22, 25]. Whilst this approach was expected to produce a set of genes with high-confidence of their
- 621 involvement in disorder risk, it is not exhaustive and it will be important to ensure risk gene lists are
- updated as more evidence from GWAS and other studies becomes available [25, 53]. Genes that are
- thought to confer resistance to the development of neuropsychiatric disease are also beginning to
- 624 emerge and the addition investigation of their expression and isoform profiles may also provide
- valuable insight into disease risk and progression [77]. In future, combining whole or amplicon
- transcriptomic data, large-scale proteomic data and machine-learning predictive models like TRIFID
- 627 can help to identify and prioritise functional proteomic isoforms [78].

628 Conclusion

- 629 In conclusion, we identified hundreds of unreported RNA isoforms and novel exons, many of which
- 630 could impact the function of known neuropsychiatric risk genes that also play crucial roles in normal631 neuronal development and activity. An understanding of the regulatory and functional impacts of
- neuronal development and activity. An understanding of the regulatory and functional impacts of
 these novel isoforms and incorporating long-read Nanopore data into existing repositories will help
- 652 these nover isolotins and incorporating long-read Nanopore data into existing repositories will help
- 633 form an important knowledge base of alternative splicing in the human brain [79, 80]. Some novel
- 634 isoforms or exons may also be future therapeutic targets through the modulation of splice isoforms
- 635 using antisense oligonucleotides or CRISPR technology.

636 Methods

637 Sample preparation and QC

638 Healthy control post-mortem human brain samples were obtained from six individuals collected

- through the Victorian Brain Bank (VBB) under HREC approvals #12457 and #28304. Age, sex and
- 640 additional details including the post-mortem interval (PMI), pH and tissue weight are shown in
- 641 Supplementary Table 1. Briefly, samples comprised 5 males and 1 female, age range: 51 72 yrs,
- 642 PMI range: 31 64 hrs and pH range: 5.7 6.7. Due to low RNA integrity number equivalent (RINe)
- 643 the female control was removed from further analysis. Frozen tissue (weight range: 57 135 mg) was
- 644 cut from seven brain regions including Brodmann areas (BA), BA9 (dorsolateral prefrontal cortex
- 645 (DLPFC)), BA46 (medial prefrontal cortex (MPFC)), BA10 (fronto-parietal cortex (FPC)), Brodmann
- Area 24 (dorsal anterior cingulate cortex (dACC)), caudate, cerebellum and temporal cortex. Total
- 647 RNA was extracted from bulk tissue in eight randomised batches of 3 6 samples. First, frozen brain
- tissue was homogenised on ice, using a manual tissue grinder (Potter-Elvehjem, PTFE), whilst
- 649 immersed in 1 mL QIAzol Lysis Reagent (QIAGEN). Lysate was then processed using a RNeasy
- Lipid Tissue Kit (QIAGEN, 74804), according to the manufacturers' instructions. Isolated RNA
- 651 quality and quantity was checked using a Qubit 4 Fluorometer (2 μ L), TapeStation 4200 (RINe: cut-
- 652 off = 6) and Nanodrop 2000.

653 Database curation and risk gene selection

- 654 MHD risk genes were selected for long-read amplicon sequencing using an internal database that
- aimed to collate evidence from the literature of gene involvement in disease risk from the original
- 656 GWAS, meta-analyses including MAGMA (and variants including eMAGMA, hMAGMA,
- nMAGMA), TWAS, SMR and follow-up studies including fine mapping, protein-protein interaction
- 658 (PPI), epigenetic (DNA methylation) and targeted experimental validation (Supplementary Figure 1).
- 659 The foundation of this database was a list of significant GWAS SNPs for SZ, BD, MDD and ASD.
- Association data was downloaded from the NHGRI-EBI GWAS Catalog [81]. MHD GWAS
- associations were filtered on the 'Disease/Trait' column to exclude effects of treatments including
- 662 pharmaceutical, mixed disorder studies and associations with behavioural traits like smoking or
- alcohol intake. Associations were excluded if both the 'reported gene' column was 'not reported
- 664 (NR)' and the 'mapped gene' column was blank. Date data was downloaded, filters applied, and
- 665 percentage associations retained are detailed in Supplementary Table 4.
- Follow-up studies and experiments were then identified in the literature and the reported genes weremanually collated and assigned to an 'evidence' category (i.e.: MAGMA, SMR, experimental
- validation etc). Each evidence category had the following information headers including the PubMed
- 669 ID of the reporting manuscript, the first author and the reported SNP and gene. An R script was used
- to curate risk genes and appearances in unique studies. Counts of reported risk genes and unique
- 571 studies, for each evidence category, were then combined with the original GWAS table. Risk genes
- 672 were then sorted by evidence (high to low), separately for each MHD. A multi-trait evidence list was
- also made by combining each MHD table together and again sorting by descending evidence. This
- 674 gave us flexibility to focus on risk genes that appeared to be specific to a single MHD or those with
- 675 shared risk across disorders.

676 Primer design, cDNA synthesis and long-range PCR

- 677 Thirty-one (31) MHD risk genes were selected from our database and the full coding sequence (CDS)
- from the canonical isoform was downloaded from the UCSC Genome Browser [82]. Primers, located
- in the 5' and 3' UTRs, were designed to amplify the CDS using Primer3 Plus [83]. Additional primers

680 were made to amplify alternative start or end sites that were not captured by a single primer pair.

- 681 Additional UCSC track sources including expressed sequence tags (EST), transcript support level
- 682 (TSL), APPRIS designation, human mRNA support, cap-analysis of gene expression (CAGE) peaks,
- 683 CpG islands and H3K4Me3 marks were examined to ensure there was enough evidence that
- alternative start or end sites were real before a primer was designed [82]. All primers, primer
- 685 combinations and modified Primer3 Plus settings are listed in Supplementary Table 3. Risk gene
- primers from Primer3 Plus were aligned to tracks on the UCSC Genome Browser using BLAT for
- 687 visualisation and tested using the In-Silico PCR [82].
- 688 To amplify risk gene CDS, 1 μg of total RNA was used as template for cDNA synthesis using
- 689 Maxima H Minus Reverse Transcriptase (Thermo Fisher Scientific, EP0752, 200 U/µL) according to
- the manufacturers' instructions. Two duplicate cDNA plates were generated simultaneously to reduce
- variability and provide enough template for multiple risk gene PCRs. Risk genes were amplified using
- one of following DNA polymerases; LongAmp® Taq 2X Master Mix (NEB, M0287S), Platinum[™]
 SuperFi II PCR Master Mix (Thermo Fisher Scientific, 12368010) or PrimeSTAR GXL (TakaraBio,
- SuperFi II PCR Master Mix (Thermo Fisher Scientific, 12368010) or PrimeSTAR GXL (TakaraBio,
 R050B). Each set of gene primers were individually optimised by adjusting PCR cycling conditions
- (Supplementary Table 3) until sufficient pure template ($\sim 1 10$ ng) could be produced for input to
- barcoding. Short-fragments and primer-dimer were removed prior to barcoding using AMPure XP
- beads (Beckmann Coulter) at 0.5 0.8x ratios. An overview of the experimental protocol is shown in
- 698 Figure 1A.

699 Long-read amplicon sequencing

- Barcoding conditions for sample multiplexing (N=35, EXP-PBC096, ONT) and library preparation
- for long-read sequencing followed the recommended ligation sequencing protocol (Figure 1A) (SQK-
- LSK109/110, ONT). All barcoding PCR was done using LongAmp® Taq 2X Master Mix with an
- amplicon specific extension time (approximately $1 \min/Kb$) and 10 15x cycles. AMPure clean-up
- following adaptor ligation was adjusted from the default ratio of 0.4X depending on the length of the
- 705target amplicon. Adaptor ligated libraries were loaded (25 35 fmol) onto MinION (FLO-MIN106)
- flow cells and a minimum of 10,000 reads per sample were targeted before flushing and storing the
- flow cell. All runs were re-basecalled using the super-accurate (SUP) basecalling model (Guppy
- v6.0.17, 2022) and minimum qscore = 10.

709 Isoform discovery from long-read amplicon sequencing with IsoLamp

- 710 We developed a new bioinformatic pipeline, IsoLamp, for the analysis of long-read amplicon data
- 711 (Figure 1B). First, pass reads were down sampled [84] to a consistent number (8000) per barcode and
- mapped to the reference genome with minimap2 (v2.24) [37]. Then, low accuracy reads (\geq 5% error
- 713 rate) were removed and samples were merged prior to isoform identification. Read accuracy was
- calculated using CIGAR strings in the BAM files and is defined as: ('X'+'='+'I'+'D'-
- 'NM')/('X'+'='+'I'+'D'). Next, the merged BAM file of high accuracy reads was used as input for
- isoform discovery with Bambu (v3.2.4) using the following parameters: novel discovery rate (NDR) = (NDR)
- 1 and min.fractionByGene = 0.001 [38]. Next, isoforms identified with Bambu were filtered to
- remove any with zero expression and to retain only isoforms overlapping the known primer
- coordinates using bedtools intersect (v2.30) [85]. Finally, the remaining isoforms were used to create
- an updated transcriptome with GffRead (v0.12.7) [86], and reads from each barcode were quantified $\frac{1}{2}$
- with salmon in alignment-based mode (v0.14.1) [87] and isoforms were annotated with GffCompare
- 722 (v0.12.6) [86]. The pipeline outputs a list of isoform annotations (.gtf), isoform expression as
- transcripts per million (TPM) and proportion of overall gene expression, as well as a report
- summarising the results. An optional TPM filter was also applied to further filter isoforms which

required a minimum TPM of 5000. If the user specifies a grouping variable for their input samples, a
t-test is performed between isoform proportions between groups and a false discovery rate of 0.05 is
applied.

- We benchmarked the performance of the IsoLamp pipeline using Spike-in RNA Variant (SIRV) Set 1
 synthetic RNA controls (Lexogen). SIRV isoforms are present in three mixes (E0, E1, E2) that
 contain isoforms in varying known concentrations. Primers were designed to amplify from the first to
- the last exon (as described above) of SIRV5 and SIRV6 genes from cDNA generated in triplicate
- from each SIRV mix (N=27) (Supplementary Figure 2). PCR amplification conditions for SIRV
- amplicons are shown in Supplementary Table 5. Samples were barcoded and sequenced as described
- above, and subsequent basecalling and demultiplexing was performed with Guppy (v6.0.17, SUP,
- 7352022). The IsoLamp pipeline was compared against four other isoform discovery tools: StringTie2
- [41], FLAIR [39], FLAMES [40] and Bambu [38] (using both default parameters and the optimised
- parameters used in IsoLamp). The sensitivity, specificity, accuracy and correlations (expected versus
 observed counts) of the programs were compared using three SIRV reference annotations: complete
- 739 (C), incomplete (I) (missing isoforms, to test ability to recover unannotated true positive isoforms)
- and over (O) (extra isoforms, to test ability to minimise false positive annotated isoforms). Novel
- isoforms were categorised using SQANTI (v4.2) against the human reference (GENCODE release 41,
- GRCh38.p13). Finally, a combined dataset of expression values for each known and novel isoform
- 743 and its associated metadata including brain region, gene, RINe, pH, individual, PMI and age was
- analysed using principal component analysis (PCA).

745 Novel exon validation

- 746 Nanopore long-read supported novel exons were validated by RT-PCR. Amplicons were designed
- from the known 5' flanking exon into the novel exon and from the novel exon into the known 3'
- flanking exon. An amplicon spanning the known 5' and 3' flanking exons was used as a positive
- control. Primers were designed using Primer3 [83] and checked using Primer BLAST [88] and are
- 750 listed in Supplementary Table 6. In some cases, the primer design space was restricted by the novel
- exon sequence length and/or nucleotide composition. Novel exons were amplified using *Taq* 2X
- 752 MasterMix (NEB, M0270L) and cycling conditions can be found in Supplementary Table 6. PCR
- 753 products were visualised via gel electrophoresis using GelGreen® Nucleic Acid Stain (Biotium,
- 41005) and GeneRuler 100 bp ladder (TFS, SMN0243). PCR products in the expected size range were
- cleaned up using AMPure XP Reagent (Beckmann Coulter, A63881) at a 1.8X ratio to remove
- fragments <100 bp and sent for Sanger sequencing (100 200 bp, AGRF).

757 Protein isolation and novel sequence detection using targeted mass spectrophotometry (MS)

- 758 Post-mortem frontal cortex and cerebellum brain samples (mean weight = 53.25 mg) were used for
- protein isolation. Samples were from a 59 yo female and 74 yo male, with PMIs of 30 and 22 hrs
- respectively, who had no known neurological or neuropsychiatric conditions. Samples were lysed in
- 761 500 μ L of guanidinium-HCl buffer using tip-probe sonication, heated briefly to 95 °C and diluted 1:1
- with LC-MS water before 4 mL of ice-cold acetone was added to precipitate protein overnight at -30
- ⁷⁶³ °C. Following a wash (3 mL 80% cold acetone) and incubation (-30 °C, 1 hr) supernatant was
- discarded and protein air-dried (RT, 30 mins). The protein pellet was resuspended in 500 μL 10%
- TFE in 100 mM HEPES (pH 7.5) and sonicated. Protein concentration was estimated with BCA (1 μ L
- sample + 9 μ L 2% SDS). Normalised protein (10 μ g/10 μ L) was then digested using a combination of
- 767 LysC/trypsin or GluC for all samples. Peptides were separated on a Dionex 3500 nanoHPLC, coupled
- to an Orbitrap Lumos mass spectrometer (Thermo Fisher Scientific) via electrospray ionization in
 positive mode with 1.9 kV at 275 °C and RF set to 30%. Separation was achieved on a 50 cm × 75

- ⁷⁷⁰ μm column packed with C18AQ (1.9 μm; Dr Maisch, Ammerbuch, Germany) (PepSep, Marslev,
- 771 Denmark) over 120 min at a flow rate of 300 nL/min. The peptides were eluted over a linear gradient
- of 3–40% Buffer B (Buffer A: 0.1% v/v formic acid; Buffer B: 80% v/v acetonitrile, 0.1% v/v FA)
- and the column was maintained at 50 °C. The instrument was operated in targeted M2 acquisition
- mode with an MS1 spectrum acquired over the mass range 300-1300 m/z (120,000 resolution, 100%)
- automatic gain control (AGC) and 50 ms maximum injection time) followed by targeted MS/MS via
- HCD fragmentation with 0.7 m/z isolation (60,000 resolution, 200% AGC, 300 ms maximum
- injection time and stepped normalised collision energy 25, 30 and 35 eV). Data were analysed in
- Proteome Discover v2.5.0.400 with SequestHT [89] and searched against a custom .fasta database
- containing only risk gene predicted protein isoform sequences containing the targeted peptide
- sequences. Precursor mass tolerance was set to 10 ppm and fragment mass tolerance set to 0.02 Da.
- Data were filtered to 1% FDR at the peptide spectral match level only i.e. no protein level FDR, and
 MS/MS annotations were manually verified. Protein structure prediction was done using AlphaFold
- MS/MS annotations were manually verified. Protein structure prediction was done usi
 accessed through UCSF ChimeraX (v1.5) [45, 51, 90].
- 784 Statistics
- 785 Statistical results presented in this manuscript included linear regression to investigate RNA yield and
- 786 quality (RIN) against individual, pH and PMI. Ordinary one-way ANOVAs using Tukey's multiple
- 787 comparison correction were used to analyse isoform TPMs between brain regions. Statistical tests and
- associated graphical output were performed using GraphPad Prism 10.1.0.

789 Isoform data visualisation

- 790 The publicly available web-tool IsoVis (v1.6, https://isomix.org/isovis/) was used to visualise RNA
- 791 isoforms and associated expression data (Wan et al., 2024, *under review*). Known and novel RNA
- isoforms are represented as a stack to compare alternative splicing events between different isoforms.
- 793 Read counts assigned to each RNA isoform for each of the 35 samples were visualised as a heatmap.

794

795 **Declarations**

796 Ethics approval

- 797 Healthy control post-mortem human brain samples were obtained from six consented individuals
- collected by the Victorian Brain Bank (VBB) and the Human Research Ethics Committee of the
- 799 University of Melbourne gave ethical approval for this work: #12457 and #28304.

800 Consent for publication

- 801 The VBB obtained signed consent for whole-brain donation from either the donor or their next-of-kin
- in which the signed person states: "I agree that research data gathered from studies may be published
- 803 providing the donor cannot be identified." All samples mentioned in this study have been de-
- identified and, except VBB pathologist CM, authors were blinded to any other individual details
- 805 beyond those mentioned in the methods.

806 Availability of data and materials

- 807 All raw nanopore long-read data (fastq) generated for each of the genes reported in this manuscript
- are available at The European Genome-Phenome Archive (EGA) study: EGAS00001007744. Gene
- 809 isoform GTFs and TPM data from IsoLamp analysis are available upon request. Scripts used for risk
- 810 gene evidence curation and downstream data analysis are available upon request. IsoLamp is open

source and freely available at https://github.com/ClarkLaboratory/IsoLamp. IsoVis is freely available
 at https://isomix.org/isovis/.

813 Competing interests

- 814 RDP, YP, YY, JG and MBC have received financial support from Oxford Nanopore Technologies
- 815 (ONT) to present their findings at scientific conferences. ONT played no role in study design,
- 816 execution, analysis or publication.
- 817 Funding
- 818 This work was supported by the Leichtung Family through the Brain and Behavior Foundation
- NARSAD Young Investigator Grant [27184 to MBC] and an Australian National Health and Medical
 Research Council Investigator Grant [GNT1196841 to MBC].

821 Author contributions

- 822 MBC conceived the study. SJ, YP and JG wrote the IsoLamp software with testing assistance from
- 823 RDP, RA, AL, EMW, YS, RK. SJ, RC and RDP wrote the code to analyse and collate the risk gene
- database. CM performed pathology analysis and classified post-mortem brain tissues. RDP performed
- 825 RNA extraction, long-read experiments and bioinformatic analysis with assistance from YP, YY, RA,
- AL, AH, EMW, YS and RK. MD and BLP extracted protein, ran mass spectrophotometry and
- analysed results. MBC and RDP oversaw the research. RDP and MBC wrote the paper with input and
- 828 review from all authors.

829 Acknowledgements

- 830 The authors would like to acknowledge that brain tissues were received from the Victorian Brain
- 831 Bank (VBB), supported by The Florey, The Alfred and the Victorian Institute of Forensic Medicine
- and funded in part by Parkinson's Victoria, MND Victoria and FightMND. The authors would also
- 833 like to thank Geoff Pavey at the VBB for his assistance with frozen tissue preparation. This research
- 834 was supported by The University of Melbourne's Research Computing Services and the Petascale
- 835 Campus Initiative.

836 **References**

- Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ: Deep surveying of alternative splicing
 complexity in the human transcriptome by high-throughput sequencing. *Nature genetics* 2008, 40:1413-1415.
- Kelemen O, Convertini P, Zhang Z, Wen Y, Shen M, Falaleeva M, Stamm S: Function of
 alternative splicing. *Gene* 2013, 514:1-30.
- Nilsen TW, Graveley BR: Expansion of the eukaryotic proteome by alternative splicing.
 Nature 2010, 463:457-463.
- Leung SK, Jeffries AR, Castanho I, Jordan BT, Moore K, Davies JP, Dempster EL, Bray NJ,
 O'Neill P, Tseng E: Full-length transcript sequencing of human and mouse cerebral cortex
 identifies widespread isoform diversity and alternative splicing. *Cell reports* 2021, 37.
- Mazin P, Xiong J, Liu X, Yan Z, Zhang X, Li M, He L, Somel M, Yuan Y, Phoebe Chen YP:
 Widespread splicing changes in human brain development and aging. *Molecular systems biology* 2013, **9**:633.
- Baralle FE, Giudice J: Alternative splicing as a regulator of development and tissue identity.
 Nature reviews Molecular cell biology 2017, 18:437-451.
- 7. De Paoli-Iseppi R, Gleeson J, Clark MB: Isoform Age-Splice Isoform Profiling Using Long 853 Read Technologies. Frontiers in Molecular Biosciences 2021, 8.
- 8. Castaldi PJ, Abood A, Farber CR, Sheynkman GM: Bridging the splicing gap in human
 genetics with long-read RNA sequencing: finding the protein isoform drivers of disease.
 Human Molecular Genetics 2022, 31:R123-R136.
- Stanley RF, Abdel-Wahab O: Dysregulation and therapeutic targeting of RNA splicing in cancer. Nature cancer 2022, 3:536-546.
- Vitting-Seerup K, Sandelin A: IsoformSwitchAnalyzeR: analysis of changes in genome-wide
 patterns of alternative splicing and its functional consequences. *Bioinformatics* 2019,
 35:4469-4471.
- Manuel JM, Guilloy N, Khatir I, Roucou X, Laurent B: Re-evaluating the impact of alternative
 RNA splicing on proteomic diversity. *Frontiers in Genetics* 2023, 14:1089053.
- Melé M, Ferreira PG, Reverter F, DeLuca DS, Monlong J, Sammeth M, Young TR, Goldmann
 JM, Pervouchine DD, Sullivan TJ: The human transcriptome across tissues and individuals.
 Science 2015, 348:660-665.
- Carvill GL, Engel KL, Ramamurthy A, Cochran JN, Roovers J, Stamberger H, Lim N, Schneider
 AL, Hollingsworth G, Holder DH: Aberrant inclusion of a poison exon causes dravet
 syndrome and related SCN1A-associated genetic epilepsies. The American Journal of
 Human Genetics 2018, 103:1022-1029.
- 14. Lara-Pezzi E, Desco M, Gatto A, Gómez-Gaviro MV: Neurogenesis: regulation by alternative
 splicing and related posttranscriptional processes. *The Neuroscientist* 2017, 23:466-477.
- 873 15. Rehm J, Shield KD: Global Burden of Disease and the Impact of Mental and Addictive
 874 Disorders. Current Psychiatry Reports 2019, 21:10.
- Sandell C, Kjellberg A, Taylor RR: Participating in diagnostic experience: adults with
 neuropsychiatric disorders. Scandinavian Journal of Occupational Therapy 2013, 20:136 142.
- Bray NJ, O'Donovan MC: The genetics of neuropsychiatric disorders. Brain and neuroscience
 advances 2018, 2:2398212818799271.
- 18. Medalia A, Saperstein AM, Hansen MC, Lee S: Personalised treatment for cognitive
 dysfunction in individuals with schizophrenia spectrum disorders. Neuropsychological
 rehabilitation 2018, 28:602-613.
- Mora C, Zonca V, Riva MA, Cattaneo A: Blood biomarkers and treatment response in major
 depression. Expert review of molecular diagnostics 2018, 18:513-529.
- 885 20. Anney RJL, Ripke S, Anttila V, Grove J, Holmans P, Huang H, Klei L, Lee PH, Medland SE, Neale
- 886 B, et al: Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder

887		highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia.
888		Molecular Autism 2017, 8: 21.
889	21.	Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, Pallesen J, Agerbo E, Andreassen
890		OA, Anney R: Identification of common genetic risk variants for autism spectrum disorder.
891		Nature genetics 2019, 51: 431-444.
892	22.	Pardiñas AF, Holmans P, Pocklington AJ, Escott-Price V, Ripke S, Carrera N, Legge SE, Bishop
893		S, Cameron D, Hamshere ML: Common schizophrenia alleles are enriched in mutation-
894		intolerant genes and in regions under strong background selection. Nature genetics 2018,
895		50: 381.
896	23.	Ripke S, Neale BM, Corvin A, Walters JT, Farh K-H, Holmans PA, Lee P, Bulik-Sullivan B, Collier
897		DA, Huang H: Biological insights from 108 schizophrenia-associated genetic loci. Nature
898		2014, 511: 421.
899	24.	Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V, Mattheisen M, Wang Y,
900		Coleman JR, Gaspar HA: Genome-wide association study identifies 30 loci associated with
901		bipolar disorder. Nature genetics 2019, 51:793-803.
902	25.	Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, Bryois J, Chen
903		C-Y, Dennison CA, Hall LS: Mapping genomic loci implicates genes and synaptic biology in
904		schizophrenia. Nature 2022, 604:502-508.
905	26.	Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, Montgomery GW, Goddard ME,
906		Wray NR, Visscher PM: Integration of summary data from GWAS and eQTL studies predicts
907		complex trait gene targets. Nature genetics 2016, 48:481-487.
908	27.	Sey NY, Hu B, Mah W, Fauni H, McAfee JC, Rajarajan P, Brennand KJ, Akbarian S, Won H: A
909		computational tool (H-MAGMA) for improved prediction of brain-disorder risk genes by
910		incorporating brain chromatin interaction profiles. Nature Neuroscience 2020, 23:583-593.
911	28.	Yang A, Chen J, Zhao X-M: nMAGMA: a network-enhanced method for inferring risk genes
912		from GWAS summary statistics and its application to schizophrenia. Briefings in
913		bioinformatics 2021, 22: bbaa298.
914	29.	Devlin B, Kelsoe JR, Sklar P, Daly MJ, O'Donovan MC, Craddock N, Sullivan PF, Smoller JW,
915		Kendler KS: Genetic relationship between five psychiatric disorders estimated from
916		genome-wide SNPs. Nature genetics 2013, 45:984-994.
917	30.	Hyde TM, Lipska BK, Ali T, Mathew SV, Law AJ, Metitiri OE, Straub RE, Ye T, Colantuoni C,
918		Herman MM: Expression of GABA signaling molecules KCC2, NKCC1, and GAD1 in cortical
919		development and schizophrenia. Journal of Neuroscience 2011, 31:11088-11095.
920	31.	Wang Z, Chen W, Cao Y, Dou Y, Fu Y, Zhang Y, Luo X, Kang L, Liu N, Shi YS, et al: An
921		independent, replicable, functional and significant risk variant block at intron 3 of
922		CACNA1C for schizophrenia. Australian & New Zealand Journal of Psychiatry 2022, 56:385-
923		397.
924	32.	Steijger T, Abril JF, Engström PG, Kokocinski F, Hubbard TJ, Guigó R, Harrow J, Bertone P:
925		Assessment of transcript reconstruction methods for RNA-seq. Nature methods 2013,
926		10: 1177-1184.
927	33.	Amarasinghe SL, Su S, Dong X, Zappia L, Ritchie ME, Gouil Q: Opportunities and challenges
928		in long-read sequencing data analysis. Genome biology 2020, 21:1-16.
929	34.	Glinos DA, Garborcauskas G, Hoffman P, Ehsan N, Jiang L, Gokden A, Dai X, Aguet F, Brown
930		KL, Garimella K: Transcriptome variation in human tissues revealed by long-read
931		sequencing. Nature 2022, 608:353-359.
932	35.	Clark MB, Wrzesinski T, Garcia AB, Hall NAL, Kleinman JE, Hyde T, Weinberger DR, Harrison
933		PJ, Haerty W, Tunbridge EM: Long-read sequencing reveals the complex splicing profile of
934 025	26	the psychiatric risk gene CACNA1C in human brain. <i>Molecular Psychiatry</i> 2020, 25 :37-47.
935	36.	Ma L, Semick SA, Chen Q, Li C, Tao R, Price AJ, Shin JH, Jia Y, Consortium B, Brandon NJ:
936 027		Schizophrenia risk variants influence multiple classes of transcripts of sorting nexin 19
937		(SNX19). <i>Molecular psychiatry</i> 2020, 25: 831-843.

938	37.	Li H: Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics 2018,
939		34: 3094-3100.
940	38.	Chen Y, Sim A, Wan YK, Yeo K, Lee JJX, Ling MH, Love MI, Göke J: Context-aware transcript
941		quantification from long-read RNA-seq data with Bambu. Nature Methods 2023:1-9.
942	39.	Tang AD, Soulette CM, van Baren MJ, Hart K, Hrabeta-Robinson E, Wu CJ, Brooks AN: Full-
943		length transcript characterization of SF3B1 mutation in chronic lymphocytic leukemia
944		reveals downregulation of retained introns. Nature communications 2020, 11:1438.
945	40.	Tian L, Jabbari JS, Thijssen R, Gouil Q, Amarasinghe SL, Voogd O, Kariyawasam H, Du MR,
946		Schuster J, Wang C: Comprehensive characterization of single-cell full-length isoforms in
947		human and mouse with long-read sequencing. Genome biology 2021, 22:1-24.
948	41.	Kovaka S, Zimin AV, Pertea GM, Razaghi R, Salzberg SL, Pertea M: Transcriptome assembly
949		from long-read RNA-seq alignments with StringTie2. Genome biology 2019, 20:1-13.
950	42.	Tardaguila M, De La Fuente L, Marti C, Pereira C, Pardo-Palacios FJ, Del Risco H, Ferrell M,
951		Mellado M, Macchietto M, Verheggen K: SQANTI: extensive characterization of long-read
952		transcript sequences for quality control in full-length transcriptome identification and
953		quantification. Genome research 2018, 28:396-411.
954	43.	Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD, Bairoch A: ExPASy: the proteomics
955		server for in-depth protein knowledge and analysis. Nucleic acids research 2003, 31:3784-
956		3788.
957	44.	Pihl R, Jensen RK, Poulsen EC, Jensen L, Hansen AG, Thøgersen IB, Dobó J, Gál P, Andersen
958		GR, Enghild JJ: ITIH4 acts as a protease inhibitor by a novel inhibitory mechanism. Science
959		advances 2021, 7: eaba7381.
960	45.	Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates
961		R, Žídek A, Potapenko A: Highly accurate protein structure prediction with AlphaFold.
962		Nature 2021, 596: 583-589.
963	46.	Schreiner D, Nguyen T-M, Russo G, Heber S, Patrignani A, Ahrné E, Scheiffele P: Targeted
964		combinatorial alternative splicing generates brain region-specific repertoires of neurexins.
965		Neuron 2014, 84: 386-398.
966	47.	Joglekar A, Prjibelski A, Mahfouz A, Collier P, Lin S, Schlusche AK, Marrocco J, Williams SR,
967	.,	Haase B, Hayes A, et al: A spatially resolved brain region- and cell type-specific isoform
968		atlas of the postnatal mouse brain. Nature Communications 2021, 12: 463.
969	48.	Kamran M, Laighneach A, Bibi F, Donohoe G, Ahmed N, Rehman AU, Morris DW:
970	101	Independent Associated SNPs at SORCS3 and Its Protein Interactors for Multiple Brain-
971		Related Disorders and Traits. Genes 2023, 14:482.
972	49.	Dong F, Wu C, Jiang W, Zhai M, Li H, Zhai L, Zhang X: Cryo-EM structure studies of the
973	45.	human VPS10 domain-containing receptor SorCS3. Biochemical and Biophysical Research
974		Communications 2022, 624: 89-94.
975	50.	Breiderhoff T, Christiansen GB, Pallesen LT, Vaegter C, Nykjaer A, Holm MM, Glerup S,
976	50.	Willnow TE: Sortilin-related receptor SORCS3 is a postsynaptic modulator of synaptic
977		depression and fear extinction. <i>PloS one</i> 2013, 8 :e75006.
978	51.	Mirdita M, Schütze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M: ColabFold: making
	51.	
979	52	protein folding accessible to all. Nature methods 2022, 19 :679-682.
980	52.	Mullins N, Forstner AJ, O'Connell KS, Coombes B, Coleman JR, Qiao Z, Als TD, Bigdeli TB,
981		Børte S, Bryois J: Genome-wide association study of more than 40,000 bipolar disorder
982	50	cases provides new insights into the underlying biology. <i>Nature genetics</i> 2021, 53 :817-829.
983	53.	Kim M, Vo DD, Jops CT, Wen C, Patowary A, Bhattacharya A, Yap CX, Zhou H, Gandal MJ:
984		Multivariate variance components analysis uncovers genetic architecture of brain isoform
985		expression and novel psychiatric disease mechanisms. <i>medRxiv</i> 2022:2022.2010.
986	Γ 4	2018.22281204.
987	54.	Yeo G, Holste D, Kreiman G, Burge CB: Variation in alternative splicing across human
988		tissues. Genome biology 2004, 5:1-15.

989 55. Sarantopoulou D, Brooks TG, Nayak S, Mrčela A, Lahens NF, Grant GR: Comparative 990 evaluation of full-length isoform quantification from RNA-Seq. BMC bioinformatics 2021, 991 **22:**1-24. 992 56. Hu Y, Fang L, Chen X, Zhong JF, Li M, Wang K: LIQA: long-read isoform quantification and 993 analysis. Genome biology 2021, 22:182. 994 57. Zhang C, Zhang B, Lin L-L, Zhao S: Evaluation and comparison of computational tools for 995 RNA-seg isoform quantification. BMC genomics 2017, 18:1-11. 996 58. Arendt-Tranholm A, Mwirigi JM, Price TJ: RNA isoform expression landscape of the human 997 dorsal root ganglion (DRG) generated from long read sequencing. *bioRxiv* 2023:2023.2010. 998 2028.564535. 999 59. Ganley IG, Lam DH, Wang J, Ding X, Chen S, Jiang X: ULK1· ATG13· FIP200 complex mediates 1000 mTOR signaling and is essential for autophagy. Journal of Biological Chemistry 2009, 1001 284:12297-12305. 1002 60. Alers S, Löffler AS, Paasch F, Dieterle AM, Keppeler H, Lauber K, Campbell DG, Fehrenbacher 1003 B, Schaller M, Wesselborg S, Stork B: Atg13 and FIP200 act independently of Ulk1 and Ulk2 1004 in autophagy induction. Autophagy 2011, 7:1424-1433. 1005 61. Leppek K, Das R, Barna M: Functional 5' UTR mRNA structures in eukaryotic translation 1006 regulation and how to find them. Nature reviews Molecular cell biology 2018, 19:158-174. 1007 62. Baum ML, Wilton DK, Fox RG, Carey A, Hsu Y-HH, Hu R, Jäntti HJ, Fahey JB, Muthukumar AK, 1008 Salla N: CSMD1 regulates brain complement activity and circuit development. Brain, 1009 Behavior, and Immunity 2024. 1010 Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, 63. 1011 Rosenthal A, Barres BA: Complement and microglia mediate early synapse loss in 1012 Alzheimer mouse models. Science 2016, 352:712-716. 1013 64. Alsabban AH, Morikawa M, Tanaka Y, Takei Y, Hirokawa N: Kinesin Kif3b mutation reduces 1014 NMDAR subunit NR 2A trafficking and causes schizophrenia-like phenotypes in mice. The 1015 EMBO Journal 2020, 39:e101090. 1016 65. Woźniak MJ, Allan VJ: Cargo selection by specific kinesin light chain 1 isoforms. The EMBO 1017 Journal 2006, 25:5457-5468. 1018 66. Imbrici P, Conte Camerino D, Tricarico D: Major channels involved in neuropsychiatric 1019 disorders and therapeutic perspectives. Frontiers in Genetics 2013, 4. 1020 67. Guzman RE, Miranda-Laferte E, Franzen A, Fahlke C: Neuronal CIC-3 splice variants differ in 1021 subcellular localizations, but mediate identical transport functions. Journal of Biological 1022 Chemistry 2015, 290:25851-25862. 1023 68. Duncan AR, Polovitskaya MM, Gaitán-Peñas H, Bertelli S, VanNoy GE, Grant PE, O'Donnell-1024 Luria A, Valivullah Z, Lovgren AK, England EM: Unique variants in CLCN3, encoding an 1025 endosomal anion/proton exchanger, underlie a spectrum of neurodevelopmental 1026 disorders. The American Journal of Human Genetics 2021, 108:1450-1465. 1027 69. Roca-Umbert A, Garcia-Calleja J, Vogel-González M, Fierro-Villegas A, Ill-Raga G, Herrera-1028 Fernández V, Bosnjak A, Muntané G, Gutiérrez E, Campelo F: Human genetic adaptation 1029 related to cellular zinc homeostasis. Plos Genetics 2023, 19:e1010950. 1030 70. Perez Y, Shorer Z, Liani-Leibson K, Chabosseau P, Kadir R, Volodarsky M, Halperin D, Barber-Zucker S, Shalev H, Schreiber R: SLC30A9 mutation affecting intracellular zinc homeostasis 1031 1032 causes a novel cerebro-renal syndrome. Brain 2017, 140:928-939. 1033 71. Willekens J, Runnels LW: Impact of Zinc Transport Mechanisms on Embryonic and Brain 1034 Development. Nutrients 2022, 14:2526. 1035 72. Lee J, Joo E-J, Lim H-J, Park J-M, Lee KY, Park A, Seok A, Lee H, Kang H-G: Proteomic analysis 1036 of serum from patients with major depressive disorder to compare their depressive and 1037 remission statuses. Psychiatry investigation 2015, 12:249. 1038 73. Piñeiro M, Andrés M, Iturralde M, Carmona S, Hirvonen J, Pyörälä S, Heegaard PMH, 1039 Tjørnehøj K, Lampreave F, Piñeiro A, Alava MA: ITIH4 (Inter-Alpha-Trypsin Inhibitor Heavy


1040		Chain 4) Is a New Acute-Phase Protein Isolated from Cattle during Experimental Infection.
1041		Infection and Immunity 2004, 72: 3777-3782.
1042	74.	Prawer YD, Gleeson J, De Paoli-Iseppi R, Clark MB: Pervasive effects of RNA degradation on
1043	75	Nanopore direct RNA sequencing. NAR Genomics and Bioinformatics 2023, 5:lqad060.
1044	75.	Harrison PJ, Heath PR, Eastwood SL, Burnet PWJ, McDonald B, Pearson RCA: The relative
1045		importance of premortem acidosis and postmortem interval for human brain gene
1046		expression studies: selective mRNA vulnerability and comparison with their encoded
1047	70	proteins. Neuroscience Letters 1995, 200 :151-154.
1048	76.	Karst SM, Ziels RM, Kirkegaard RH, Sørensen EA, McDonald D, Zhu Q, Knight R, Albertsen M:
1049		High-accuracy long-read amplicon sequences using unique molecular identifiers with
1050		Nanopore or PacBio sequencing. Nature methods 2021, 18 :165-169.
1051	77.	Hess JL, Tylee DS, Mattheisen M, Børglum AD, Als TD, Grove J, Werge T, Mortensen PB: A
1052		polygenic resilience score moderates the genetic risk for schizophrenia. Molecular
1053	70	psychiatry 2021, 26 :800-815.
1054	78.	Pozo F, Martinez-Gomez L, Walsh TA, Rodriguez JM, Di Domenico T, Abascal F, Vazquez J,
1055		Tress ML: Assessing the functional relevance of splice isoforms. NAR Genomics and
1056		Bioinformatics 2021, 3 :Iqab044.
1057	79.	Amaral P, Carbonell-Sala S, De La Vega FM, Faial T, Frankish A, Gingeras T, Guigo R, Harrow
1058		JL, Hatzigeorgiou AG, Johnson R, et al: The status of the human gene catalogue. Nature
1059	~~	2023, 622 :41-47.
1060	80.	Frankish A, Carbonell-Sala S, Diekhans M, Jungreis I, Loveland JE, Mudge JM, Sisu C, Wright
1061		JC, Arnan C, Barnes I: GENCODE: reference annotation for the human and mouse genomes
1062		in 2023. Nucleic acids research 2023, 51:D942-D949.
1063	81.	Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, McMahon A,
1064		Morales J, Mountjoy E, Sollis E: The NHGRI-EBI GWAS Catalog of published genome-wide
1065		association studies, targeted arrays and summary statistics 2019. Nucleic acids research
1066	~~	2019, 47 :D1005-D1012.
1067	82.	Nassar LR, Barber GP, Benet-Pagès A, Casper J, Clawson H, Diekhans M, Fischer C, Gonzalez
1068		JN, Hinrichs AS, Lee BT: The UCSC genome browser database: 2023 update. Nucleic acids
1069	00	research 2023, 51 :D1188-D1195.
1070	83.	Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, Leunissen JA: Primer3Plus, an
1071	0.4	enhanced web interface to Primer3. Nucleic acids research 2007, 35:W71-W74.
1072	84.	Bushnell B: BBMap: a fast, accurate, splice-aware aligner. Lawrence Berkeley National
1073	05	Lab.(LBNL), Berkeley, CA (United States); 2014.
1074	85.	Quinlan AR: BEDTools: the Swiss-army tool for genome feature analysis. <i>Current protocols</i>
1075		in bioinformatics 2014, 47: 11.12. 11-11.12. 34.
1076	86.	Pertea G, Pertea M: GFF utilities: GffRead and GffCompare. F1000Research 2020, 9.
1077	87.	Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C: Salmon provides fast and bias-aware
1078	00	quantification of transcript expression. <i>Nature methods</i> 2017, 14 :417-419.
1079	88.	Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL: Primer-BLAST: a tool to
1080		design target-specific primers for polymerase chain reaction. BMC bioinformatics 2012,
1081		13: 1-11.
1082	89.	Eng JK, McCormack AL, Yates JR: An approach to correlate tandem mass spectral data of
1083		peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 1994,
1084	00	5:976-989.
1085	90.	Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, Morris JH, Ferrin TE: UCSF
1086		ChimeraX: Structure visualization for researchers, educators, and developers. Protein
1087	04	Science 2021, 30: 70-82.
1088	91.	Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, Hasz R, Walters G, Garcia F, Young
1089		N: The genotype-tissue expression (GTEx) project. Nature genetics 2013, 45:580-585.
1090		

1092 Supplementary Figures

1093 Supplementary Figure 1. Mental health disorder (MHD) risk gene list curation pipeline. A.

Single nucleotide polymorphism (SNP) catalogues form the foundation of the final risk gene evidencelists used to select genes for amplicon sequencing. These catalogues are collated from up-to-date,


- 1095 Insist used to select genes for amplicon sequencing. These catalogues are contact from up-to-date,1096 large-scale genome wide association studies (GWAS) of MHDs. A single GWAS catalogue was
- 1097 downloaded for schizophrenia (SZ), major depressive disorder (MDD), bipolar disorder (BD) and
- 1098 autism spectrum disorder (ASD), and associations were filtered according to criteria in Supplementary
- 1099 Table 4. GWAS data generally had either a mapped or reported gene associated with each SNP.
- 1100 Further evidence (i.e. reported genes) from categorised literature sources (shown in green) was then
- added to the list. This list was then sorted (high to low) by the number of occurrences of a risk gene in
- unique studies across all evidence/validation categories. No weighting was applied to any category. A
 multi-trait list was also made containing evidence for risk genes across all four MHDs so shared risk
- 1104 genes could be identified. **B.** An example of additional risk gene information included in the list e.g.
- 1105 for *GNL3*, count of known transcripts, count of coding exons for the canonical isoform, length in
- nucleotides (nt), length of protein in amino acids (aa) and the categorised Genotype-Tissue
- 1107 Expression (GTEx) in transcript per million (TPM) for each brain tissue [91]. Definitions: multi-
- 1108 marker analysis of Genomic annotation (MAGMA), summary-based Mendelian randomisation
- 1109 (SMR), transcriptome wide association study (TWAS).



Supplementary Figure 2. Experimental design of SIRV amplicon controls. E0, E1 and E2 represent


each SIRV mix of known isoform concentrations. Each mix was converted into cDNA in triplicate

- and finally, the full length of synthetic genes SIRV5 and 6 were amplified using PCR in triplicate for
- 1113 each cDNA replicate.



1115 Supplementary Figure 3. Benchmarking IsoLamp using spike-in SIRVs and the optimised


- 1116 IsoLamp expression-based filter. A. Precision recall of each tested pipeline with the complete,
- 1117 insufficient or over annotated SIRV reference, filtering all results using the IsoLamp expression-based
- 1118 filter. IsoLamp (black) returned high quality isoforms from amplicon data of both SIRV5 and 6.
- 1119 Pearson (B) and Spearman (C) correlations for each pipeline between known and observed expression
- 1120 values for SIRV 5 and 6 mixes.
- 1121



Supplementary Figure 4. Post-mortem human brain RNA QC. A. Yield of isolated total 1123 RNA generally increases with increased tissue weight (mg) input to homogenisation using the 1124 RNeasy Lipid Tissue Mini Kit (QIAGEN:74804). B. The RNA integrity number equivalent 1125 (RINe) for brain tissue was generally between 7 - 8. RINe from individual (Ind) 04 was 1126 significantly lower when compared to individuals 01 (p=0.0259) and 05 (p=0.0433). One way 1127 ANOVA: F=6.224, DF=6. C. No correlation was detected between RNA guality (RINe) and 1128 individual post-mortem interval (PMI). D. Decreasing individual brain pH appears to impact 1129 RINe. Half-fill circles indicate samples from individual 04 (pH = 6.3). Filled circles indicate 1130 degraded RNA isolated from individual 06 (female)w which was not included for further 1131 1132 analysis. Data in B, C and D are staggered for clarity.


1133 A

В




1136 Supplementary Figure 5. Principal component analyses (PCA) of brain samples. PC1 and PC2

- 1137 coloured by brain region (A) and RNA integrity (RIN) (B). C. PC4 and PC5 coloured by donor age
- (years). Key: individual (IND), Brodmann's area (BA), caudate (caud), cerebellum (cbm) andtemporal cortex (TCX).



1145 Supplementary Figure 6. Long-read amplicon mapping accuracy. A. All sequenced risk genes.


- 1146 Plotted range 0.85 1.00. **B.** A box and whiskers plot of the median accuracy for each risk gene.
- 1147 Open circles indicate the library was prepared with ligation sequencing kit 110 (ONT). Colours
- 1148 indicate flow cells (prefix: FAL) that were used for multiple long-read libraries (N=3-5).
- 1149 A




1150

1151

B



Supplementary Figure 7. Risk gene isoform counts. The number of detected isoforms (known and novel) is shown for each risk gene sorted from lowest (*GRIN2A*) to highest (*ITIH4*). Each isoform was classified into a SQANTI subcategory: reference match (RM), containing at least one novel splice site (ALO), retained intron (RI), combination of known junctions (COJ) or splice sites (COS). Known (RM) isoform counts are plotted on the right Y-axis and novel isoform counts are plotted on the left Y-axis.




1160

1161 Supplementary Figure 8. Linear regression of amplicon length or canonical exon count against

1162 isoform count and novel isoform TPM proportion does not deviate significantly from zero.


1163 Linear regression of known and novel isoform counts with expected canonical amplicon length (A)

- and number of canonical exons (B). Linear regression of novel isoform read proportion with expected
- 1165 canonical amplicon length (C) and number of canonical exons (D).




1171 Supplementary Figure 9. A. Count of novel isoform splice pairing. Isoforms classified as containing

- at least one novel splice site (ALO) were examined and the novel pair or donor/acceptor was counted.
- 1173 Duplicates were counted only once. **B.** UCSC screenshot of an example novel splice acceptor (red
- box, GT/AG, +98 nt) detected in two novel isoforms (Tx 11 and 23) in canonical exon 17 (blue box)
- 1175 for the schizophrenia risk gene *CPT1C*.
- 1176 A









1180 Supplementary Figure 10. UCSC screenshot of CACNA1C splicing hotspot. Long-read

- sequencing identified 10 novel isoforms (black tracks) that support one of two annotated alternative
- splicing events (yellow boxes) within a 12 nt region (chr12:2,493,190-2,493,201) of exon 7 in
- 1183 *CACNA1C*. 11 novel isoforms also supported the use of the canonical (ENST00000399655.6)
- 1184 acceptor site (green box).
- 1185



- **Supplementary Figure 11.** Annotated MS/MS spectrum highlighting matched b- and y-type ions
- 1189 providing proteomic [ETLFSVMPG//PVLPGGALGISSSIR] evidence for novel skipping of canonical
 1100 even 22 in *ITHUA* detected using long mode.
- exon 22 in *ITIH4* detected using long-reads.




1192 Supplementary Figure 12. NEGR1 splice isoforms and protein prediction. A. NEGR1 novel exons

- 1193 were validated using Sanger sequencing of PCR amplicons and sequence reads were aligned and 1194 viewed using UCSC Genome Browser. Orange boxes indicate the novel exons and highlight high
- 1195 vertebrate conservation for exon 6b and predicted (NCBI RefSeq) termination site for exon 6a. **B.**
- 1196 AlphaFold protein prediction of the canonical *NEGR1* isoform (ENST00000357731). Three Ig-like
- 1197 domains are coloured according to the reported amino-acid positions (UniProt: Q7Z3B1); 1 (orange),
- 1198 2 (blue) and 3 (pink). A GPI anchor residue (red) is shown at position 324 aa (C-terminal, red arrow).
- **1199 C.** Overlaid AlphaFold protein predictions of novel Tx1 (purple) and Tx2 (orange). Ig-like domains
- are numbered 1-3, the GPI anchor (red) is present in Tx1 and the termination of Tx is indicated by a
- red arrow. Novel residues (pink) are indicated at the C-terminal end for both transcripts, Tx1: 14 aa
- **1202** and Tx2: 7 aa.

Α

1203

1204






1206



В






1209


1210

С




1224 (UTR).








В



1229 Supplementary Figure 14. Splice graph of XRN2 novel isoforms containing novel exons. Dark


- and light grey boxes indicate 5' and 3' UTR and coding exons respectively. Orange lines and boxes
- indicate novel splicing events and exons. Novel transcript 1 (Tx1) contains a novel splice acceptor
- 1232 (AG) within exon 14 (+24 nt) leading to a premature termination codon (PTC) and predicted nonsense
- mediated decay. Novel transcript 2 (Tx2) includes the validated novel exon 16a (54 nt) which was
- also predicted to encode a PTC. Novel isoform 3 (Tx3) contains a validated novel exon (29a) which
- encodes a PTC <50 nt from the final exon junction. Tx3 was predicted to lead to a truncated protein
- 1236 (934 aa). ".." indicates 0's removed for brevity.





1240 Supplementary Figure 15. SORCS3 novel exon and protein structure predictions. A. AlphaFold

- 1241 prediction of *SORCS3* canonical isoform (ENST00000369701.8: Q17R88) coloured by domain: β-1242 β
- propeller (blue), 10CC domain domains (green), polycystic kidney disease (PKD) domains PKD1
 (orange) and PKD2 (yellow), SorCS membrane proximal (SoMP) (red) and transmembrane domain
- (orange) and PKD2 (yellow), SorCS membrane proximal (SoMP) (red) and transmembrane domain
 (pink). B. Zoomed view of the PKD2 domain indicating LYS:956 (blue) and PRO:957 (orange) where
- frame-retaining novel exon 20a (60 nt) is inserted. **C.** Protein structure prediction of novel transcript 1
- (Tx1) containing the novel exon (blue) within the PKD2 domain (yellow). **D.** AlphaFold per-residue
- 1247 confidence scores (pLDDT) (0-100) for novel transcript 1: very high (>90, blue), confident (90-70,
- 1248 light-blue), low (70>50, yellow) and very low (<50, orange).
- 1249
- 1250



1252

1251

1253 C

